following an abbreviated submission:
opicapone (Ongentys®) is accepted for use within NHSScotland.
Indication under review: as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
Opicapone provides an additional treatment choice in the therapeutic class of catechol-O-methyl transferase inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice633KB (PDF)
- Medicine name:
- opicapone (Ongentys)
- SMC ID:
Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
- Pharmaceutical company
- Bial Pharma UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 17 January 2022